Pharmaniaga allocates RM295mil for FY22 capex


KUALA LUMPUR: Pharmaniaga Bhd is allocating RM295 million for the group’s capital expenditure (capex) finances within the monetary yr 2022 (FY2022), in contrast with RM106.9 million in FY2021.

Chief monetary officer Norai’ni Mohamed Ali mentioned the capex allocation could be largely for logistics and distribution which accounted for 61 per cent, adopted by manufacturing (36 per cent) and Indonesia (three per cent).

“For logistics and distribution, we’re trying on the growth of recent warehouse, central distribution centre for the non-public sector, digitalisation, buy of software program for long-term medicine venture and migration system and buy and substitute of current warehouse and workplace tools,” she advised a digital media briefing on the corporate’s outcomes for the third quarter (Q3) ended Sept 30, 2021 at this time.

Whereas for manufacturing, she mentioned the group would proceed to make use of half of allocation to spend money on halal vaccines and halal insulin initiatives.

“To not overlook our Indonesian counterpart, we’re additionally investing in automation and digitalisation in addition to improve of assorted pc and lab tools,” she added.

In the meantime, group managing director Datuk Zulkarnain Md Eusope mentioned the group would emphasis on analysis and growth efforts which have been additionally the important thing pillars of Pharmaniaga’s development, enabling it to develop product pipeline and offering higher options to the nation.

“This was aimed to assist Malaysian authorities to be pandemic prepared sooner or later.

“Digitalisation and digital applied sciences would be the spine of those effort,” he mentioned.

Zulkarnain mentioned Pharmaniaga would proceed with the Sinovac COVID-19 vaccine fill and end manufacturing to satisfy home and worldwide calls for, because the group has the experience, capabilities and amenities in addition to full assist from technical companions from abroad.

“On the identical time, we are going to embark on organising an insulin manufacturing plant which will likely be situated at our high-tech Pharmaniaga LifeScience website in Puchong, whereas the organising of the world’s first halal vaccine plant is progressing on observe.

“On our logistics and distribution enterprise with the Ministry of Well being (MoH), we are going to proceed and presently we’re in negotiating with the federal government for the finalisation of the brand new concession/contract,” he added.

Pharmaniaga’s internet revenue for the Q3 ended Sept 30, 2021 widened to RM49.83 million from RM1.44 million registered in the identical quarter a yr in the past, whereas income jumped to RM2.13 billion from RM624.8 million, attributed to the constructive development throughout the group’s concession, non-concession and Indonesian companies.

The non-concession enterprise was a key driver on account of gross sales of the Sinovac COVID-19 vaccine to the MoH in addition to the non-public sector.

The corporate has declared a 3rd interim dividend of two sen per share with ex date on Dec 6, 2021, entitlement date on Dec 7 and payable on Dec 29, 2021. – Bernama

Source link